Century Therapeutics, Inc. (IPSC)

Market Cap	62.08M
Revenue (ttm)	2.68M
Net Income (ttm)	-129.89M
Shares Out	85.03M
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	279,655
Open	0.760
Previous Close	0.749
Day's Range	0.724 - 0.765
52-Week Range	0.681 - 5.510
Beta	1.74
Analysts	Strong Buy
Price Target	11.00 (+1,406.64%)
Earnings Date	Mar 13, 2025

About IPSC

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relaps...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 165
• Stock Exchange: NASDAQ
• Ticker Symbol: IPSC
• Website: https://www.centurytx.com

Financial Performance

In 2023, Century Therapeutics's revenue was $2.24 million, a decrease of -57.01% compared to the previous year's $5.20 million. Losses were -$136.67 million, 4.38% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 1,406.64% from the latest price.

Price Target

$11.0

(1,406.64% upside)

Analyst Consensus: Strong Buy